UroGen Pharma (URGN) Other Non-Current Liabilities (2020 - 2026)

UroGen Pharma (URGN) has reported Other Non-Current Liabilities for 7 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 2.95% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 2.95% YoY) and the FY2025 annual result came in at $3.9 million, up 2.95% from the prior year.
• Other Non-Current Liabilities held at $3.9 million in Q1 2026 per URGN's latest filing, from $3.9 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for URGN reached as high as $3.9 million in Q4 2025 and fell as low as $2.8 million in Q1 2022.
• A 5-year average of $3.3 million and a median of $3.2 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities gained 18.69% — and 2025, when it grew 2.95%.
• Year by year, Other Non-Current Liabilities stood at $3.0 million in 2022, then advanced by 5.83% to $3.2 million in 2023, then rose by 18.69% to $3.8 million in 2024, then advanced by 2.95% to $3.9 million in 2025, then changed by 0.0% to $3.9 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.9 million, $3.9 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.